Advertisement

Patterns of survival in advanced non-Hodgkin’s lymphoma

  • T. A. Reichert
  • R. A. Christensen
  • A. A. Bartolucci
  • C. Walker
Chapter
Part of the Developments in Oncology book series (DION, volume 32)

Abstract

In the development of clinical experience, certain factors come to be associated empirically with an extreme prognosis (for example, very long or very short survival). This clinical impression can be quantitated by examining the capacity such factors have to separate the patient population into two or more sub-groups each with a distinct and different survival experience. Those which univariately separate the sample population into statistically significant groupings rightfully assume a greater role in subsequent clinical thinking. Much clinical research has been devoted to comparing the survival experience of patient populations divided into subgroups by combinations of factors which make especially good clinical sense. Unfortunately, even the number of clinically sensible combinations is very large; and the testing of so multiple a hypothesis has its own pitfalls.

Keywords

Favorable Histology Unfavorable Histology Good Prognosis Patient Entropy Limited Karnofsky Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cox DR (1972). Regression models and life-tables. J Roy Stat Soc B 34: 187–202.Google Scholar
  2. 2.
    Christensen R (1984). Entropy minimax. In: Singh M (Ed.). Encyclopedia of Systems and Control. Oxford: Pergamon Press (in Press).Google Scholar
  3. 3.
    Durant JR, Gams RA, Bartolucci AA and Dorfman RF (1977). BCNU with and without cyclophosphamide, vincristine and prednisone ( COP) and cycle-active therapy in non-hodgkin’s lymphoma. Cancer Treat Rep 61: 1085–1096.Google Scholar
  4. 4.
    Gams RA, Rainey M, Bartolucci AA and Dandy M. Phase III study of BCOP vs. CHOP in unfavorable categories of malignant lymphoma. J Clin Oncol (in Press).Google Scholar
  5. 5.
    Christensen RA, Eilbert R, Reichert TA (1984). Self-consistent estimates of individual survival expectancy from censored data. (Submitted for publication June, 1984 ).Google Scholar
  6. 6.
    Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations. Amer Stat Assoc J 53: 457–481.CrossRefGoogle Scholar
  7. 7.
    Christensen RA (1981). Entropy Minimax Sourcebook, Vol. IV, Chap. 14, p. 355: Applications. Lincoln, MA.: Entropy Limited.Google Scholar
  8. 8.
    The Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982). National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Cancer 49: 2112–2135.CrossRefGoogle Scholar
  9. 9.
    Portlock CS and Rosenberg SA (1979). No initial therapy for Stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 90: 10–13.PubMedGoogle Scholar
  10. 10.
    Diggs CH, Wiernik PH and Ostrow SS (1981). Nodular Lymphoma: Prolongation of survival by complete remission. Cancer Clin Trials 4: 107–114.PubMedGoogle Scholar
  11. 11.
    Anderson T, Bener RA, Fisher RI et al. (1977). Combination chemotherapy in non-Hodgkin’s lymphomas: Results of long-term follow-up. Cancer Treat Rep 61: 1057–1066.PubMedGoogle Scholar
  12. 12.
    Longo D, Hubbard Wesley M, Jaffe E et al. 1981 ). Prolonged initial remission in patients with nodular mixed lympoma ( NML ). Proc Amer Soc Clin Oncol 22: 521.Google Scholar
  13. 13.
    Bitran JC, Golomb HM, Ultmann JE et al. (1978). Non-Hodgkin’s lymphoma, poorly differentiated lymphocytic and mixed cell types: Results of sequential staging procedures, response to therapy and survival of 100 patients. Cancer 42: 88–95.PubMedCrossRefGoogle Scholar
  14. 14.
    Glick JH, Barnes JM, Ezdinli EZ et al. (1981). Nodular mixed lymphoma: Results of a randomized trial failing to confirm prolonged disease-free survival with chemotherapy. Blood 58: 920–925.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • T. A. Reichert
    • 1
  • R. A. Christensen
    • 2
  • A. A. Bartolucci
    • 3
  • C. Walker
    • 1
  1. 1.Division of Hematology/OncologyDuke University Medical CenterDurhamUSA
  2. 2.Entropy LimitedLincolnUSA
  3. 3.Statistical Center, SECSGUniversity of AlabamaBirminghamUSA

Personalised recommendations